Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
- Conditions
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00001087
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 103
- Registration Number
- NCT00000893
- Locations
- 🇺🇸
The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States
🇺🇸Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States
Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
- Conditions
- Locations
- 🇺🇸
Univ of Hawaii, Honolulu, Hawaii, United States
🇺🇸Beth Israel Med Ctr, New York, New York, United States
🇺🇸Tripler Army Med Ctr, Tripler AMC, Hawaii, United States
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 40
- Registration Number
- NCT00004585
- Locations
- 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Tower Infectious Diseases / Med Associates Inc, Los Angeles, California, United States
🇺🇸North Shore Univ Hosp, Manhasset, New York, United States
Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
- Conditions
- First Posted Date
- 2001-07-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00018083
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
- Conditions
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 25
- Registration Number
- NCT00001758
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.